Reaction: Darolutamide to 1 product

Reaction
Darolutamide
DB12941
Ketodarolutamide
DB15647
Reaction type
Not Available
Direction
Major circulating metabolite?
No
Spontaneous?
No
Activity
unknown
References
  1. Fizazi K, Smith MR, Tombal B: Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. Clin Genitourin Cancer. 2018 Oct;16(5):332-340. doi: 10.1016/j.clgc.2018.07.017. Epub 2018 Jul 24. [Article]
  2. FDA Approved Drug Products: NUBEQA (darolutamide) tablets, for oral use [Link]
Comments
Not Available
Enzymes
EnzymeKmVmaxRole
Cytochrome P450 3A4Not AvailableNot Availableconfirmed
UDP-glucuronosyltransferase 1-9Not AvailableNot Availableconfirmed